**Top Industries:**
1. Biopharmaceuticals
2. Vaccines
3. Blood plasma products

**Top 3 Markets and their Percentage Shares:**
1. South Korea: 45%
2. USA: 30%
3. Europe: 15%

GC Biopharma Corp. generates the majority of its revenues from the biopharmaceutical industry, with vaccines and blood plasma products making a significant contribution. The home market of South Korea remains the largest market for the company, followed by the USA, where there is strong demand for innovative biopharmaceutical solutions. Europe represents the third largest market, with the company benefiting from increasing acceptance of its products.

**Production sites of GC Biopharma Corp.:**

1. **Main production facility:** Yongin, South Korea
2. **Additional production facilities:** Ochang, South Korea

GC Biopharma Corp., formerly known as Green Cross Corporation, produces the majority of its biopharmaceutical products in South Korea. The main production facility is located in Yongin, while another significant facility is in Ochang. These sites are central to the manufacturing of vaccines, blood plasma derivatives, and other biopharmaceutical products of the company.

**Focus on Biotechnology Innovations:** GC Biopharma Corp. is increasingly focusing on the development of new biotechnological products to strengthen its market position.

**Expansion of International Presence:** The company plans to export its products to new international markets to reduce dependence on the domestic market.

**Investments in Research and Development:** GC Biopharma is increasing spending on research and development to bring innovative therapies and medications to market faster.

GC Biopharma Corp. is pursuing a strategy aimed at innovation and internationalization. By expanding its research and development departments and entering new markets, the company aims to sustainably secure its growth. These measures are intended not only to expand the product range but also to strengthen global market presence.

**Main raw materials:** Plasma, chemicals for the production of biopharmaceuticals

**Countries of origin:** USA, Germany, China

GC Biopharma Corp. mainly imports plasma and specific chemicals needed for the production of their biopharmaceutical products. The USA is a significant supplier of plasma due to its well-developed infrastructure for plasma collection. Germany provides high-quality chemicals and biotechnological components essential for production. China is also an important partner, especially for more cost-effective chemical raw materials and intermediates.

This import structure enables GC Biopharma to produce high-quality products while optimizing costs through a diversified supply chain.

**Market share in South Korea:** 25% (2026, estimated)
**R&D investments:** 12% of revenue (2025)
**Patents:** Over 150 active patents (2026)

GC Biopharma Corp. has a significant competitive advantage in the South Korean market, especially due to its high market share of about 25%. This is supported by continuous investments in research and development, which account for approximately 12% of revenue.

The company has a strong pipeline of innovative products protected by over 150 active patents. These patents not only secure existing products but also promote the development of new therapies, further strengthening the competitive position.

In addition, GC Biopharma benefits from a solid infrastructure and an established distribution network that solidifies its market presence in Asia and beyond. The focus on quality and innovation helps to gain and maintain the trust of customers and partners.

**Institutional Investor Share:** Estimated at 45% (2026)

**Insider Buys/Sells:** No significant transactions reported (2026)

The institutional investor share in GC Biopharma Corp. is estimated to be around 45%. This suggests that a significant number of shares are held by investment funds, pension funds, and other large institutional investors.

Regarding insider buys or sells, no significant transactions have been reported in the recent reporting periods. This could indicate that the management and other insiders are currently not making significant changes to their holdings, which may signal stable confidence in the company's development.

These pieces of information are based on the latest available data and industry comparisons.

**Market share of GC Biopharma Corp.:** 4.5% (estimated for 2026)

**Top competitors and their market shares:**
1. **Samsung Biologics:** 12.0%
2. **Celltrion:** 10.5%
3. **SK Bioscience:** 8.0%
4. **Hanmi Pharmaceutical:** 6.5%
5. **LG Chem:** 5.0%
6. **GC Biopharma Corp.:** 4.5%
7. **Daewoong Pharmaceutical:** 4.0%
8. **Korea United Pharm:** 3.5%
9. **Yuhan Corporation:** 3.0%
10. **JW Pharmaceutical:** 2.5%

GC Biopharma Corp. has a moderate market share compared to its competitors. The market share of 4.5% indicates that the company has a certain presence in the industry, but is not among the market leaders.

The moat of GC Biopharma Corp. is less pronounced compared to leading companies like Samsung Biologics and Celltrion. These companies benefit from larger economies of scale, more extensive research and development resources, and a stronger international presence.

However, GC Biopharma Corp. could have a certain advantage through specialized products or niche markets. Nevertheless, the moat is considered less significant compared to the top competitors. To strengthen the moat, the company could invest in innovative technologies or exclusive partnerships.

**Revenue Growth:** 8.9% (2025)
**Research and Development Ratio:** 12% of revenue (2025)
**Market Share in the Biopharma Sector:** 4.5% (2025)

GC Biopharma Corp. recorded a revenue growth of 8.9% in 2025, attributed to a successful expansion of their product range and a stronger market presence. The company continues to heavily invest in research and development, with a ratio of 12% of revenue, indicating a strategic focus on innovation and future growth.

The 4.5% market share in the Biopharma sector shows that GC Biopharma holds a significant position in the industry. These factors suggest that the company is well positioned to benefit from future market opportunities, especially through new product developments and potential market expansions.

Overall, GC Biopharma Corp. could present an attractive investment opportunity, especially for investors interested in long-term growth and innovation.

**Dividend Yield:** 2.5% (2026, estimated)
**Dividend History:** Consistent payout over the last 5 years

GC Biopharma Corp. has been paying a consistent dividend in recent years, indicating a reliable payout policy. The dividend yield is currently estimated at 2.5%, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payments is supported by the company's stable financial performance. The continuous payout over the last five years shows that GC Biopharma aims to provide shareholders with a regular return. Analysts believe that the company will also be able to maintain dividends in the future, provided that no significant negative market changes occur.